Fecal Pellet Output

Discover how Melior’s unique phenotypic screening platforms can uncover the untapped value of your candidate therapeutic

A simple and noninvasive means of evaluating gastrointestinal function involves measuring fecal pellet output over a given time period(s).  This can involve not only pellet counts but also measuring total wet weight, total dry weight and descriptive observations.  In turn these measures can be used to calculate average weight / pellet and wet versus dry ratio which provides a measure of moisture content while also serving as a colonic transit test.

This model is 1 of more than 60 models included in our theraTRACE® platform

Learn more

Ready to get started or looking for a custom model?

Contact us today for more information about our bespoke research models and to discuss how we can help you answer your unique research questions.

Discuss your project with us

The study illustrated below shows how the inhibition of colonic motility by morphine results in reduced fecal pellet output

Interested in running an Insulin Tolerance Test study?

If you are interested in learning more about the Insulin Tolerance Test (ITT), please contact us to start the conversation today!

Discuss your project with us
  • We chose Melior Discovery because they were responsive and cost effective.  We are staying with them as a chosen scientific partner because of their thoughtful scientific input to experimental design and attention to detail.  Their expertise and flexibility allowed us to quickly adapt the study design and evaluate additional outcome measures to pursue unexpected activity.

    Sridharan Rajamani, Ph.D., Senior Research Scientist

    Gilead Sciences
  • I have been working with Melior on a number of projects over the course of a few years now.  They have been a great partner throughout this time.  The scientists whom I have worked with have been great problem-solvers and were customer focused.

    Jay Lichter

    Avalon Ventures
  • Melior provided State-of-the-art Preclinical Pharmacology Support for a period of nearly a year where a series of in vivo studies were completed on a weekly basis. The staff was extremely user-friendly and the operational processes were excellent. I can recommend Melior without reservation.

    Richard DiMarchi, PhD

    Cox Professor of Chemistry & Gill Chair in Biomolecular Sciences Indiana University, Department of Chemistry
  • Because Melior could do the orthotopic intracranial implants, we were able to do survival studies with brain tumor-bearing animals that were treated with our therapy, showing a beautiful survival with our agent versus control. Talk about something that gets your investors going! These beautiful survival curves with our agent versus control and visual photos are in all of our investor decks because… it's powerful.

    Bruce Ruggeri, Ph.D.

    Modifi Bio
  • Melior works in many therapeutic areas, like CNS, inflammatory disease, GI, cardiovascular, and oncology. I was very pleased that when it came to doing tumor studies, both subcutaneous and intracranial, they did them well. They reported on the studies on time and did the data analysis really well.

    Bruce Ruggeri, Ph.D.

    Modifi Bio
  • Their areas of expertise are extensive, and they are very experienced, responsive, and flexible in terms of how the study is run. Their pricing is reasonable, making them the best option for a young, not well-funded company like ours.

    Maxine Gowen

    Tamuro Bio
  • Melior’s team was very experienced and knowledgeable. They were always very open to suggestions and questions, spending a lot of time helping us feel comfortable with the study design. I would give them very high marks.

    Maxine Gowen

    Tamuro Bio
  • The most important factors in choosing to work with Melior were the fit between the tests they could run and our needs, as well as their tight budget and proximity. Melior was the best fit for our research goals.

    Ira Spector

    SFA Therapeutics

Blood glucose changes of mice responding to an exogenous insulin challenge.

Fecal pellet output as a colonic transit test. C57Bl/6 mice were fed ad libitum until the acclimation period at approximately 9:00 AM. Then mice were weighed, dosed with vehicle or 10 mg/kg morphine SC, singly housed in polyurethane cages without access to food, and acclimated to the procedure room for 30 minutes prior to the study, with free access to water. With a study start at approximately 9:30 AM, at each subsequent hour after administration up to 4 hours, the number of fecal pellets (A) and weights (B) was recorded.  Data are mean ± SEM and evaluated using unpaired t-test (N=10).  *p<0.05, **p<0.01, ***p<0.001.

Related models

Influenza

Pulmonary Edema

LPS – Pulmonary Inflammation

Pulmonary Fibrosis

Respiratory Depression

Interested in running a Fecal Pellet Output study?

If you are interested in learning more about evaluating gastrointestinal function using a colonic transit test such as measuring fecal pellet output, please contact us to start the conversation today!

Discuss your project with us